2.63
price up icon10.97%   0.26
after-market Dopo l'orario di chiusura: 2.59 -0.04 -1.52%
loading

Rezolute Inc Borsa (RZLT) Ultime notizie

pulisher
Jan 08, 2026

Does Rezolute Inc. stock trade at a discount to peersAnalyst Upgrade & Long-Term Safe Return Strategies - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Will Rezolute Inc. (6HV1) stock test record highs in 2025Market Activity Report & Fast Entry Momentum Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Bluefield Daily Telegraph

Jan 08, 2026
pulisher
Jan 08, 2026

Rezolute (RZLT): Wedbush Analyst Raises Price Target to $2.00 | RZLT Stock News - GuruFocus

Jan 08, 2026
pulisher
Jan 08, 2026

Why analysts upgrade Rezolute Inc. stockJuly 2025 Macro Moves & Free Fast Entry Momentum Trade Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc.RZLT - Chartmill

Jan 08, 2026
pulisher
Jan 08, 2026

Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target By Investing.com - Investing.com Canada

Jan 08, 2026
pulisher
Jan 08, 2026

Wedbush Doubles Price Target on Rezolute to $2 From $1, Keeps Neutral Rating - MarketScreener

Jan 08, 2026
pulisher
Jan 08, 2026

BTIG Reiterates Buy Rating for Rezolute (RZLT) with $5 Target Pr - GuruFocus

Jan 08, 2026
pulisher
Jan 07, 2026

Rezolute Hopes To Find A Way Forward In Congenital HI After Phase III Miss - Citeline News & Insights

Jan 07, 2026
pulisher
Jan 07, 2026

Rezolute (RZLT) Shows Promising Results in Hypoglycemia Treatmen - GuruFocus

Jan 07, 2026
pulisher
Jan 07, 2026

Can Rezolute's SunRIZE Study, Tumor HI Data Redefine Treatment For Hyperinsulinism? - Nasdaq

Jan 07, 2026
pulisher
Jan 07, 2026

Rezolute (RZLT) Analyzes Phase 3 sunRIZE Study Outcomes - GuruFocus

Jan 07, 2026
pulisher
Jan 07, 2026

Rezolute shares mixed results from Phase 3 trial for rare disease therapy - Investing.com Nigeria

Jan 07, 2026
pulisher
Jan 07, 2026

Rezolute rises as drug shows promise for rare low blood sugar disorders - TradingView — Track All Markets

Jan 07, 2026
pulisher
Jan 07, 2026

Rezolute, Inc. Shares Findings on Ersodetug's Efficacy for Congenital and Tumor Hyperinsulinism, Plans FDA Meeting to Discuss Path Forward - Quiver Quantitative

Jan 07, 2026
pulisher
Jan 07, 2026

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism - The Manila Times

Jan 07, 2026
pulisher
Jan 07, 2026

Experimental drug lets some severe hypoglycemia patients leave IV sugar behind - Stock Titan

Jan 07, 2026
pulisher
Jan 07, 2026

Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans - TipRanks

Jan 07, 2026
pulisher
Jan 07, 2026

Rezolute, Inc. Provides Insights from sunRIZE Study and EAP - TradingView — Track All Markets

Jan 07, 2026
pulisher
Jan 06, 2026

Potential Securities Fraud: Levi & Korsinsky Investigates Rezolute, Inc. (RZLT) - ACCESS Newswire

Jan 06, 2026
pulisher
Jan 06, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. ... - Bluefield Daily Telegraph

Jan 06, 2026
pulisher
Jan 06, 2026

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - PR Newswire

Jan 06, 2026
pulisher
Jan 06, 2026

Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Jan 06, 2026
pulisher
Jan 04, 2026

ATTENTION Rezolute, Inc. (RZLT) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire

Jan 04, 2026
pulisher
Jan 03, 2026

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT - FinancialContent

Jan 03, 2026
pulisher
Jan 03, 2026

Rezolute’s Phase 3 SunRIZE study for Ersodetug fails to meet primary and secondary endpoints despite analyst backing - MSN

Jan 03, 2026
pulisher
Jan 03, 2026

Shareholders Alert: Investigation Into Rezolute, Inc. (RZLT) – Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jan 03, 2026
pulisher
Jan 02, 2026

Investigation Underway: Rezolute, Inc. (RZLT)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire

Jan 02, 2026
pulisher
Jan 01, 2026

Weekly Trades: Will Rezolute Inc 6HV1 stock test record highs in 20252025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - moha.gov.vn

Jan 01, 2026
pulisher
Jan 01, 2026

Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN

Jan 01, 2026
pulisher
Dec 31, 2025

Revenue per share of Rezolute, Inc. – FWB:6HV1 - TradingView — Track All Markets

Dec 31, 2025
pulisher
Dec 31, 2025

Investors in Rezolute, Inc. (RZLT) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire

Dec 31, 2025
pulisher
Dec 31, 2025

Levi & Korsinsky Investigates Rezolute, Inc. (RZLT) Over Potential Securities Fraud Allegations - ACCESS Newswire

Dec 31, 2025
pulisher
Dec 31, 2025

Rezolute's Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing - Finviz

Dec 31, 2025
pulisher
Dec 31, 2025

INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT - The Malaysian Reserve

Dec 31, 2025
pulisher
Dec 31, 2025

Rezolute’s Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing - Insider Monkey

Dec 31, 2025
pulisher
Dec 31, 2025

Rezolute Faces Legal Scrutiny Following Disastrous Clinical Trial Results - timothysykes.com

Dec 31, 2025
pulisher
Dec 31, 2025

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Fail - GuruFocus

Dec 31, 2025
pulisher
Dec 30, 2025

Lost Money on Rezolute, Inc. (RZLT)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire

Dec 30, 2025
pulisher
Dec 30, 2025

Rezolute Faces Investor Outrage Amid Legal Scrutiny Following Trial Setback - StocksToTrade

Dec 30, 2025
pulisher
Dec 30, 2025

About Us | Oil & Gas JournalRezolute, Inc.Common Stock (NV) (Nasdaq:RZLT) Stock Quote - FinancialContent

Dec 30, 2025
pulisher
Dec 30, 2025

Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Rezolute, Inc. (RZLT) - ACCESS Newswire

Dec 30, 2025
pulisher
Dec 30, 2025

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PR Newswire

Dec 30, 2025
pulisher
Dec 30, 2025

Ongoing Rezolute, Inc. (RZLT) Investigation: Protect Your Rights – Contact Levi & Korsinsky - ACCESS Newswire

Dec 30, 2025
pulisher
Dec 29, 2025

Rezolute Stock: A Deluge of Turmoil - StocksToTrade

Dec 29, 2025
pulisher
Dec 29, 2025

RZLT ALERT: Levi & Korsinsky Investigates Rezolute, Inc. for Possible Securities Fraud Violations - ACCESS Newswire

Dec 29, 2025
pulisher
Dec 27, 2025

INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile

Dec 27, 2025
pulisher
Dec 26, 2025

Rezolute downgraded to neutral from overweight at Cantor Fitzgerald - MSN

Dec 26, 2025
pulisher
Dec 26, 2025

Investigation Opened on Behalf of Rezolute, Inc. (RZLT) ShareholdersContact Levi & Korsinsky - ACCESS Newswire

Dec 26, 2025
pulisher
Dec 24, 2025

ATTENTION RZLT Shareholders: Lost Money on Rezolute, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Dec 24, 2025
pulisher
Dec 24, 2025

Ongoing Investigation into Rezolute, Inc. (RZLT): Contact Levi & Korsinsky About Potential Fraud - ACCESS Newswire

Dec 24, 2025
pulisher
Dec 24, 2025

Jefferies’ Bullish Price Target Boosts Rezolute Amid Congenital Hyperinsulinism Data Anticipation - StocksToTrade

Dec 24, 2025
pulisher
Dec 24, 2025

RZLT Stock Surge: Buy or Let Go? - StocksToTrade

Dec 24, 2025
pulisher
Dec 24, 2025

Jefferies Raises Rezolute Target to Spur Stock Optimism - timothysykes.com

Dec 24, 2025
$106.87
price up icon 0.90%
$34.26
price up icon 1.87%
$118.64
price up icon 10.48%
$99.85
price up icon 1.01%
biotechnology ONC
$337.89
price up icon 5.47%
$175.97
price up icon 3.35%
Capitalizzazione:     |  Volume (24 ore):